



Market Announcement

15 May 2025

Chimeric Therapeutics Limited (ASX: CHM) – Trading Halt

Description

The securities of Chimeric Therapeutics Limited ('CHM') will be placed in trading halt at the request of CHM, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 19 May 2025 or when the announcement is released to the market.

Issued by

ASX Compliance



15 May 2025

Inderprit Singh
Adviser, Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Via email

Dear Inderprit

Chimeric Therapeutics Limited (ASX: CHM)

Request for trading halt

In accordance with ASX Listing Rule 17.1, Chimeric Therapeutics Limited (ASX: CHM) (the **Company**) requests that its securities be placed into an immediate trading halt pending an announcement in relation to new data for the ADVENT-AML Phase 1B clinical trial (NCT05834244).

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Monday, 19 May 2025, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains
Joint Company Secretary